| Bioactivity | QKY-613 is a prodrug that enhances immune surveillance by targeting nucleic acid modification pathways. QKY-613 promotes the selective incorporation of 6mdA (N6-methyldeoxyadenosine) into viral DNA, enhancing the phase separation potential of DNA, thereby increasing the activation of cGAS and strengthening host immune surveillance. In virus-infected mouse models, QKY-613 significantly reduced mortality in aged mice. QKY-613 holds promise for research on nucleic acid modification-based immune surveillance mechanisms[1]. |
| CAS | 2484713-92-8 |
| Formula | C27H31N6O7P |
| Molar Mass | 582.54 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wang N, et al. Host RNA N6-methyladenosine and incoming DNA N6-methyldeoxyadenosine modifications cooperatively elevate the condensation potential of DNA to activate immune surveillance. Mol Ther. 2024 Dec 4;32(12):4418-4434. |
QKY-613
CAS: 2484713-92-8 F: C27H31N6O7P W: 582.54
QKY-613 is a prodrug that enhances immune surveillance by targeting nucleic acid modification pathways. QKY-613 promotes
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.